Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04316936 · ClinicalTrials.gov registry record · Phase 4

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

A Phase 4 study of Cataract Surgery, sponsored by Silverstein Eye Centers.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target
1
Study location

NCT04316936 is a Phase 4 study of Cataract Surgery that has completed, run by Silverstein Eye Centers. The registered enrollment target is 15 participants, below the 144-participant average among 7 other Cataract Surgery trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04316936, a Phase 4 study of Cataract Surgery, has completed, sponsored by Silverstein Eye Centers.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.

Conditions Studied

Interventions

  • DRUG Prednisolone Acetate 1%
  • DRUG Omidria
  • DRUG Dextenza (dexamethasone ophthalmic insert) 0.4mg
  • DRUG Dexycu, 9% Intraocular Suspension

Study Locations (1)

Missouri

  • Silverstein Eye Centers - Kansas City

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-12-10
Est. Completion 2020-12-23
Phase Phase 4

Sponsor

Silverstein Eye Centers

1 total trials

What the Registry Record Tells You About NCT04316936

The ClinicalTrials.gov registry entry for NCT04316936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 7 other Cataract Surgery trials with a reported enrollment target (90% lower). The listed sponsor is Silverstein Eye Centers, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract Surgery appearing as the primary indexed condition, and to 4 interventions - of which Prednisolone Acetate 1% is the first listed.

NCT04316936 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT04316936 about?

NCT04316936 is a clinical study titled "Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery". This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.

What is the current status of trial NCT04316936?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2019-12-10. Estimated completion is 2020-12-23.

What conditions does trial NCT04316936 study?

This clinical trial studies the following conditions: Cataract Surgery.

What interventions are being tested in trial NCT04316936?

The interventions under investigation include: Prednisolone Acetate 1% (DRUG), Omidria (DRUG), Dextenza (dexamethasone ophthalmic insert) 0.4mg (DRUG), Dexycu, 9% Intraocular Suspension (DRUG).

Who is sponsoring clinical trial NCT04316936?

This trial is sponsored by Silverstein Eye Centers, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04316936 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.